Adam Costello February 10, 2016 Ticker Updates
As it reflects the theoretical cost of buying the company’s shares, the market cap of Novo Nordisk A/S (NYSE:NVO) is currently rolling at 97988.27, making it one of the key stocks in today’s market. Hence, the existing market cap indicates a preferable measure in comprehending the size of the company rather than its worth.
Novo Nordisk A/S’s P/E ratio is measuring at 23.28 with a forward P/E of 19.19. The powerful forward P/E ratio allows investors a quick snapshot of the organization’s finances without getting involved in the complicated details of the accounting report.
The PEG for Novo Nordisk A/S is gauging a 2.02, signposting the future growth of the company’s earnings. The existing PEG value acts as a measure that takes into account its future growth where investors are able to scale the company’s high-growth stock as undervalued.
As of now, Novo Nordisk A/S has a P/S value of 6.08, measuring P/B at 17.16. Its P/Cash is valued at 32.18, allowing investors to have a useful look at the company’s value in contrast to the P/E ratio. The current P/C value outlines the company’s ability to generate cash relative to its stock price rather than what it records on earnings relative to its stock price.
The dividend for the corporation to company shareholders is rolling at 1.55% with a payout ratio of 38.60%. The current value of the dividend depicts the significance to the relationship between company and its investors. With many preferring that Novo Nordisk A/S reinvest its earnings back into its trade to fuel future growth, a lot acknowledges a generous cash dividend payment. For the income oriented investors, the existing payout ratio will be observed closely, providing a valuable insight into Novo Nordisk A/S’s dividend policy.
The EPS of Novo Nordisk A/S is strolling at 2.02, measuring its EPS growth this year at 34.00%. As a result, the company has an EPS growth of 8.41% for the approaching year. Company’s EPS for the past five years is valued at 8.41%, leading it to an EPS value of 11.50% for the next five years.
Company’s sales growth for the past five years is valued at 12.20%, leading it to the present-day share price of 47.02. It has a change in price of 0.00% and a target price of 60.1.
Novo Nordisk A/S has a ROA of 41.50%, measuring the amount of profit the company earns on the value of its shares. The value of its return on investment (ROI) is 85.00%, measuring the gain/loss on its investment relative to the amount of money invested. With its flexible approach, investors can easily identify the profitability and the efficiency of the company – bearing in mind the downsides of the ROI calculation which can be manipulated.
Novo Nordisk A/S holds a quick ratio of 1 with a current ratio of 1.3. The existing figure on the company’s quick ratio portrays its ability to meet its short-term financial liabilities, and the value on the current ratio represents the company’s proficiency in dealing with its current liabilities via its current assets.
The performance for the week is valued at -15.80%, resulting in a performance for the month at -16.11%. Therefore, the stated figures displays a quarterly performance of -14.99% and an annual performance of 12.56%.
Disclaimer: Outlined statistics and information communicated in the above editorial are merely a work of the authors. They do not ponder or echo the certified policy or position of any business stakeholders, financial specialists, or economic analysts. Specimens laid down on the editorial above are only cases with information collected from various sources. The authority will not be liable for anyone who makes stock portfolio or financial decisions as per the editorial, which is based only on limited and open source information. Conclusions from the analysis of the editorial shall not depict the position of any analysts or financial professionals.
*TBA = Data not provided during this time
Popular Stories
New York’s First Medical Marijuana Dispensary Opens – So who are eligible to buy?
New York’s First Medical Marijuana Dispensary Opens – So who are eligible to buy?
Granny Reveals Her Method: Don't Use Botox, Do This Instead
Granny Reveals Her Method: Don't Use Botox, Do This Instead
The Hottest Girls Caught Doing the Dumbest Things
The Hottest Girls Caught Doing the Dumbest Things
Yuan trading higher offshore as it is designated reserve currency by IMF
Yuan trading higher offshore as it is designated reserve currency by IMF
Astronomers catches a blistering sight of the Magnetic Field Outside the Event Horizon of The Milky Way
Astronomers catches a blistering sight of the Magnetic Field Outside the Event Horizon of The Milky Way
15 Most Outrageous Plastic Surgery Fails
15 Most Outrageous Plastic Surgery Fails
Supreme Court of Hawaii called off the construction of world’s tallest telescope TMT
Supreme Court of Hawaii called off the construction of world’s tallest telescope TMT
Google’s verily announced collaboration with Johnson and Johnson on surgical spinoff
Google’s verily announced collaboration with Johnson and Johnson on surgical spinoff
?
Tags (NYSE:NVO) DRUG MANUFACTURERS - OTHER HEALTHCARE NOVO NORDISK A/S NVO NYSE